Abstract
AbstractSince the discovery of an oncogenic tropomyosin-receptor kinase (TRK) fusion protein in the early 1980s, our understanding of neurotrophic tropomyosin-receptor kinase (NTRK) fusions, their unique patterns of frequency in different tumor types, and methods to detect them have grown in scope and depth. Identification of these molecular alterations in the management of patients with cancer has become increasingly important with the emergence of histology-agnostic, US Food and Drug Administration-approved, effective TRK protein inhibitors. Herein, we review the biology of TRK in normal and malignant tissues, as well as the prevalence and enrichment patterns of these fusions across tumor types. Testing methods currently used to identify NTRK1–3 fusions will be reviewed in detail, with attention to newer assays including RNA-based next-generation sequencing. Recently proposed algorithms for NTRK fusion testing will be compared, and practical insights provided on how testing can best be implemented and communicated within the multidisciplinary healthcare team.
Publisher
Springer Science and Business Media LLC
Subject
Pathology and Forensic Medicine
Reference49 articles.
1. Pulciani, S. et al. Oncogenes in solid tumours. Nature 300, 539–542 (1982).
2. Cocco, E., Scaltriti, M. & Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 15, 731–747 (2018).
3. Schneider, R. & Schweiger, M. A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trbB tyrosine kinase receptors. Oncogene 6, 1807–1811 (2016).
4. Urfer, R. et al. An immunoglobulin-like domain determines the specificity of neurotrophin receptors. EMBO J. 14, 2795–2805 (1995).
5. Cunningham, M. E. & Greene, L. A. A function-structure model for NGF-activated TRK. EMBO J. 17, 7282–7293 (1998).
Cited by
73 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献